Cargando…

Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice

BACKGROUND: Cervical lymph node metastases are very common in papillary thyroid cancer (PTC), and typically spread in a predictable stepwise fashion in clinical practice. However, lateral lymph node metastasis (LLNM) without central lymph node metastasis (CLNM) as skip metastasis is not rare in PTC....

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Xilin, Tan, Zhou, Ge, Minghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657116/
https://www.ncbi.nlm.nih.gov/pubmed/29070029
http://dx.doi.org/10.1186/s12885-017-3698-2
_version_ 1783273825011499008
author Nie, Xilin
Tan, Zhou
Ge, Minghua
author_facet Nie, Xilin
Tan, Zhou
Ge, Minghua
author_sort Nie, Xilin
collection PubMed
description BACKGROUND: Cervical lymph node metastases are very common in papillary thyroid cancer (PTC), and typically spread in a predictable stepwise fashion in clinical practice. However, lateral lymph node metastasis (LLNM) without central lymph node metastasis (CLNM) as skip metastasis is not rare in PTC. The aim of this study was to investigate the incidence, risk factors and pattern of skip metastasis in PTC. METHODS: A total of 271 patients with PTC and suspicious LLN diagnosed by pre-operation examinations who underwent total thyroidectomy and central lymph node dissection plus lateral lymph node dissection between January 2008 and December 2011 were enrolled in this study. Clinicopathological features were collected, and the pattern of cervical lymph node metastasis and skip metastasis were analyzed. RESULTS: The LLNM rate was 74.9% (203/271, diagnosed by postoperative pathology examination) and significantly associated with extrathyroid extension (ETE), primary tumor located at the upper pole, and CLNM (p < 0.05). The skip metastasis rate was 14.8% (30/203) and was more frequently found in microcarcinoma patients, especially when the primary tumor size was ≤0.5 cm (p = 0.001 OR = 12.9). However, skip metastasis was unrelated to the remaining factors examined. CONCLUSION: Small cancers with a pre-operation diagnosis of LLNM are more likely to have skip metastases, especially when the primary tumor size is less than 0.5 cm in diameter; however, this type of metastasis appears to develop in a random fashion. Thus, additional research is needed to identify potential predictive factors, such as a primary tumor located at the upper pole.
format Online
Article
Text
id pubmed-5657116
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56571162017-10-31 Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice Nie, Xilin Tan, Zhou Ge, Minghua BMC Cancer Research Article BACKGROUND: Cervical lymph node metastases are very common in papillary thyroid cancer (PTC), and typically spread in a predictable stepwise fashion in clinical practice. However, lateral lymph node metastasis (LLNM) without central lymph node metastasis (CLNM) as skip metastasis is not rare in PTC. The aim of this study was to investigate the incidence, risk factors and pattern of skip metastasis in PTC. METHODS: A total of 271 patients with PTC and suspicious LLN diagnosed by pre-operation examinations who underwent total thyroidectomy and central lymph node dissection plus lateral lymph node dissection between January 2008 and December 2011 were enrolled in this study. Clinicopathological features were collected, and the pattern of cervical lymph node metastasis and skip metastasis were analyzed. RESULTS: The LLNM rate was 74.9% (203/271, diagnosed by postoperative pathology examination) and significantly associated with extrathyroid extension (ETE), primary tumor located at the upper pole, and CLNM (p < 0.05). The skip metastasis rate was 14.8% (30/203) and was more frequently found in microcarcinoma patients, especially when the primary tumor size was ≤0.5 cm (p = 0.001 OR = 12.9). However, skip metastasis was unrelated to the remaining factors examined. CONCLUSION: Small cancers with a pre-operation diagnosis of LLNM are more likely to have skip metastases, especially when the primary tumor size is less than 0.5 cm in diameter; however, this type of metastasis appears to develop in a random fashion. Thus, additional research is needed to identify potential predictive factors, such as a primary tumor located at the upper pole. BioMed Central 2017-10-25 /pmc/articles/PMC5657116/ /pubmed/29070029 http://dx.doi.org/10.1186/s12885-017-3698-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Nie, Xilin
Tan, Zhou
Ge, Minghua
Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice
title Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice
title_full Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice
title_fullStr Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice
title_full_unstemmed Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice
title_short Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice
title_sort skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657116/
https://www.ncbi.nlm.nih.gov/pubmed/29070029
http://dx.doi.org/10.1186/s12885-017-3698-2
work_keys_str_mv AT niexilin skipmetastasisinpapillarythyroidcarcinomaisdifficulttopredictinclinicalpractice
AT tanzhou skipmetastasisinpapillarythyroidcarcinomaisdifficulttopredictinclinicalpractice
AT geminghua skipmetastasisinpapillarythyroidcarcinomaisdifficulttopredictinclinicalpractice